Breaking News

XOMA Appoints Chief Commercial Officer

March 19, 2013

Klein brings 25 years of experience

Tom Klein has been appointed chief commercial officer at XOMA Corp. In this newly created position, he reports to chief executive officer John Varian. Mr. Klein has more than 25 years of successful brand commercialization leadership, with an expertise in commercializing biologics. Mr. Klein joins the company from Genentech, where he was vice president, business unit head of Virology and Specialty Care.
"We created an executive-level position for commercial operations for two reasons. First, we are at the point where we are ready to begin building XOMA's launch strategy and commercialization plans for gevokizumab. The importance of creating the sales and marketing plan for our first XOMA-developed product cannot be underestimated. We will build on Tom's vast experience to develop a launch program that maximizes the commercial potential of gevokizumab," said Mr. Varian.
He added, "The second reason was to fully integrate market analyses into our clinical development decisions. Tom will draw on his years of experience and to provide our team with the most accurate information that will guide our second, third and fourth gevokizumab indications. The team and I are looking forward to working closely with Tom to ensure gevokizumab is a commercial success."
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.